Sildenafil Teva
From £3.99
Understanding the Molecular Mechanisms of Action
PDE5 Enzyme Inhibition: The Core Mechanism
Sildenafil 100mg functions through selective inhibition of phosphodiesterase type 5 (PDE5), an enzyme predominantly found in penile vascular smooth muscle. When sexual arousal occurs, nitric oxide (NO) is released from nerve endings and endothelial cells within the corpus cavernosum. This NO activates the enzyme guanylate cyclase, which increases levels of cyclic guanosine monophosphate (cGMP). The cGMP acts as a secondary messenger, promoting smooth muscle relaxation and vasodilation in penile arteries.
Under normal physiological conditions, PDE5 breaks down cGMP, terminating the vasodilation process. By inhibiting PDE5, sildenafil 100mg prevents this breakdown, allowing cGMP levels to remain elevated for longer periods. This sustained elevation maintains smooth muscle relaxation and enhanced blood flow to the penis, facilitating the achievement and maintenance of erection during sexual stimulation.
Pharmacokinetic Properties and Absorption
The pharmacokinetic profile of sildenafil 100mg demonstrates rapid oral absorption with peak plasma concentrations typically reached within 30 to 120 minutes after administration. The absolute bioavailability is approximately 40%, reflecting efficient absorption despite first-pass hepatic metabolism. The drug exhibits linear pharmacokinetics across the therapeutic dose range, with the area under the curve (AUC) proportional to the administered dose.
Sildenafil undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes CYP3A4 and CYP2C9. The major circulating metabolite, N-desmethyl sildenafil, retains approximately 50% of the parent compound's PDE5 inhibitory activity. The elimination half-life averages 3-5 hours in healthy adults, though this may be prolonged in elderly patients or those with hepatic or renal impairment.
Selectivity and Specificity for PDE5
The molecular structure of sildenafil confers remarkable selectivity for PDE5 over other phosphodiesterase enzymes. This selectivity is approximately 10-fold greater than for PDE6 (found in retinal photoreceptors) and more than 80-fold greater than for PDE1. The high selectivity ratio minimises off-target effects while maximising therapeutic efficacy in penile tissue.
Crystallographic studies reveal that sildenafil binds to the active site of PDE5 through hydrogen bonding and hydrophobic interactions. The drug's structure mimics the natural substrate cGMP whilst forming more stable enzyme-inhibitor complexes. This competitive inhibition is reversible, allowing normal physiological function to resume as drug concentrations decline.
Dose-Response Relationship and Clinical Efficacy
Clinical pharmacology studies demonstrate a clear dose-response relationship for sildenafil, with 100mg representing the maximum recommended dose for most patients. Plasma concentrations show linear increases with doses from 25mg to 100mg, corresponding with enhanced therapeutic effects. The 100mg dose achieves optimal PDE5 inhibition whilst maintaining an acceptable safety profile for most men.
Efficacy studies using rigorous placebo-controlled methodology show that sildenafil 100mg significantly improves erectile function scores compared to lower doses and placebo. The International Index of Erectile Function (IIEF) demonstrates statistically significant improvements in erectile function domain scores, with effect sizes indicating clinically meaningful benefits for patients with varying degrees of erectile dysfunction severity.
Cardiovascular Pharmacology and Safety Profile
The cardiovascular effects of sildenafil 100mg result from mild PDE5 inhibition in systemic blood vessels, leading to modest vasodilation and slight reductions in blood pressure. Clinical studies show mean decreases of approximately 8-10 mmHg in systolic and 5-6 mmHg in diastolic blood pressure. These changes are generally well-tolerated in healthy men but require careful consideration in patients with cardiovascular disease.
The interaction between sildenafil and nitrates represents a critical safety consideration rooted in pharmacological mechanisms. Nitrates increase cGMP production through NO donation, whilst sildenafil prevents cGMP breakdown through PDE5 inhibition. The combination can cause dangerous hypotension through synergistic vasodilation, making concurrent use contraindicated.
Individual Variation and Personalised Medicine
Genetic polymorphisms in cytochrome P450 enzymes, particularly CYP3A4, influence individual responses to sildenafil 100mg. Patients with reduced enzyme activity may experience higher drug concentrations and prolonged effects, whilst those with enhanced metabolism may require dose adjustments. Age-related changes in hepatic function and renal clearance also contribute to inter-individual variability in drug response.
EverydayMeds offers both branded Viagra and generic sildenafil options, allowing patients to choose between equivalent formulations during the prescribing process. Both contain identical active ingredients and demonstrate bioequivalence, ensuring consistent therapeutic outcomes regardless of the selected option. The clinical assessment process considers individual patient factors to optimise treatment selection and dosing recommendations.
